Role of Dyslipidemia in Patients With Chronic Kidney Disease

References

• . National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• . Collins AJ, Foley RN, Chavers B, . United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 suppl 1):A7, e1–e420
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161–165
   PubMedGoogle Scholar
• . Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res. 2010;33(2):100–110
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. Guidelines and commentaries, http://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm. Accessed 6/19/2013
   Google Scholar
• . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Merz CN, ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Assocation. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
   PubMed Web of Science ®Google Scholar
• . Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis. 1993;22(1):105–113
   PubMedGoogle Scholar
• . Hildebrand A, Romans M, Rasmussen LM, . Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994;302(pt 2):527–534
   PubMed Web of Science ®Google Scholar
• . Zoja C, Corna D, Camozzi D, . How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13(12):2898–2908
   PubMed Web of Science ®Google Scholar
• . Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 1993;90(5):1814–1818
   PubMed Web of Science ®Google Scholar
• . Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol. 1994;267(6 pt 2):F1094–F1101
   Google Scholar
• . Ziyadeh FN, Hoffman BB, Han DC, . Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA. 2000;97(14):8015–8020
   PubMed Web of Science ®Google Scholar
• . McGowan TA, Zhu Y, Sharma K. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep. 2004;4(6):447–454
   PubMedGoogle Scholar
• . Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2(8311):1309–1311
   PubMed Web of Science ®Google Scholar
• . Michael AF, Keane WF, Raij L, Vernier RL, Mauer SM. The glomerular mesangium. Kidney Int. 1980;17(2):141–154
   PubMedGoogle Scholar
• . Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol. 1991;36(2):67–75
   PubMedGoogle Scholar
• . Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin Nephrol. 1991;36(3):127–133
   PubMedGoogle Scholar
• . Takemura T, Yoshioka K, Aya N, . Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 1993;43(4):918–927
   PubMedGoogle Scholar
• . Pai R, Kirschenbaum MA, Kamanna VS. Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int. 1995;48(4):1254–1262
   PubMedGoogle Scholar
• . Kamanna VS, Pai R, Roh DD, Kirschenbaum MA. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest. 1996;74(6):1067–1079
   PubMedGoogle Scholar
• . Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296(6):F1297–F1306
   Google Scholar
• . Kamanna VS. Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease. Histol Histopathol. 2002;17(2):497–505
   PubMed Web of Science ®Google Scholar
• . Lee HS, Kim BC, Hong HK, Kim YS. LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PKC and TGF-beta expression. Am J Physiol. 1999;277(3 pt 2):F369–F376
   Google Scholar
• . Chana RS, Wheeler DC, Thomas GJ, Williams JD, Davies M. Low-density lipoprotein stimulates mesangial cell proteoglycan and hyaluronan synthesis. Nephrol Dial Transplant. 2000;15(2):167–172
   PubMedGoogle Scholar
• . Tannock LR. Proteoglycans can mediate renal lipoprotein retention. Diabetologia. 2006;49(5):1115–1116
   PubMedGoogle Scholar
• . Thompson J, Wilson P, Brandewie K, . Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol. 2011;179(3):1179–1187
   PubMed Web of Science ®Google Scholar
• . Taneja D, Thompson J, Wilson P, . Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res. 2010;51(6):1464–1470
   PubMed Web of Science ®Google Scholar
• . Spencer MW, Muhlfeld AS, Segerer S, . Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am J Nephrol. 2004;24(1):20–31
   PubMedGoogle Scholar
• . Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29–S34
   Google Scholar
• . Samuelsson O, Attman PO, Knight-Gibson C, . Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998;9(8):1482–1488
   PubMedGoogle Scholar
• . Wanner C, Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens. 2001;10(2):195–201
   PubMedGoogle Scholar
• . Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–850
   PubMed Web of Science ®Google Scholar
• . Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis. 2000;36(2):272–281
   PubMedGoogle Scholar
• . Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301
   PubMed Web of Science ®Google Scholar
• . Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis. 1990;15(1):16–23
   PubMedGoogle Scholar
• . O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91(1):83–87
   PubMedGoogle Scholar
• . O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis. 1993;22(1):83–89
   PubMedGoogle Scholar
• . Park JK, Muller DN, Mervaala EM, . Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58(4):1420–1430
   PubMedGoogle Scholar
• . Tamura Y, Murayama T, Minami M, Yokode M, Arai H. Differential effect of statins on diabetic nephropathy in db/db mice. Int J Mol Med. 2011;28(5):683–687
   PubMed Web of Science ®Google Scholar
• . Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–1530
   PubMed Web of Science ®Google Scholar
• . van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166(1):129–135
   PubMed Web of Science ®Google Scholar
• . Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 2000;36(2):427–431
   PubMed Web of Science ®Google Scholar
• . Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21 suppl 1):II18–II26
   PubMedGoogle Scholar
• . Tonelli M, Isles C, Craven T, . Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112(2):171–178
   PubMed Web of Science ®Google Scholar
• . Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016
   PubMed Web of Science ®Google Scholar
• . Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269
   PubMed Web of Science ®Google Scholar
• . Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251–262
   PubMedGoogle Scholar
• . de Zeeuw D. Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease. Presented at: XLVII European Renal Association-European Dialysis and Transplant Association Congress; June 25–28, 2010; Munich, Germany
   Google Scholar
• . de Zeeuw D. Prospective Evaluation of Proteinuria and Renal Function in Nondiabetic Patients with Progressive Renal Disease. Presented at: XLVII European Renal Association-European Dialysis and Transplant Association Congress; June 25–28, 2010; Munich, Germany
   Google Scholar
• . Baigent C, Landray MJ, Reith C, ; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192
   PubMed Web of Science ®Google Scholar
• . Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305
   PubMed Web of Science ®Google Scholar
• . Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745–753
   PubMed Web of Science ®Google Scholar
• . Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61(4):1486–1494
   PubMed Web of Science ®Google Scholar
• . Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6):2214–2219
   PubMed Web of Science ®Google Scholar
• . Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins in chronic kidney disease. QJM. 2012;105(7):641–648
   PubMedGoogle Scholar
• . Tonelli M, Isles C, Curhan GC, . Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–1563
   PubMedGoogle Scholar
• . Wanner C, Krane V, Marz W, . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . Fellstrom BC, Jardine AG, Schmieder RE, . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–275
   PubMed Web of Science ®Google Scholar
• . Holdaas H, Fellstrom B, Jardine AG, . Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–2031
   PubMed Web of Science ®Google Scholar
• . Jardine AG, Holdaas H, Fellström B, ; ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT tudy. Am J Transplant. 2004;4(6):988–995
   PubMed Web of Science ®Google Scholar
• . Tanaka Y, Kume S, Araki S, . Fenofibrate, a PPAR alpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011;79(8):871–882
   PubMedGoogle Scholar
• . Shin SJ, Lim JH, Chung S, . Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res. 2009;32(10):835–845
   PubMedGoogle Scholar
• . Zhao YY, Weir MA, Manno M, . New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med. 2012;156(8):560–569
   PubMed Web of Science ®Google Scholar
• . Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15(12):1993–1999
   PubMed Web of Science ®Google Scholar
• . Bonds DE, Craven TE, Buse J, . Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55(6):1641–1650
   PubMedGoogle Scholar
• . Mychaleckyj JC, Craven T, Nayak U, . Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35(5):1008–1014
   PubMed Web of Science ®Google Scholar
• . Ting RD, Keech AC, Drury PL, . Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care. 2012;35(2):218–225
   PubMed Web of Science ®Google Scholar
• . Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12): 1169–1174
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66(3):1123–1130
   PubMedGoogle Scholar
• . Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44(5):832–839
   PubMedGoogle Scholar
• . Reiche I, Westphal S, Martens-Lobenhoffer J, Troger U, Luley C, Bode-Boger SM. Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney disease and dialysis patients. Nephrol Dial Transplant. 2011;26(1):276–282
   PubMedGoogle Scholar
• . Cho KH, Kim HJ, Kamanna VS, Vaziri ND. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta. 2010;1800(1):6–15
   PubMed Web of Science ®Google Scholar
• . Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia [in Spanish]. Nefrologia. 2008;28(1):61–66
   PubMed Web of Science ®Google Scholar
• . Bosch J, Gerstein HC, Dagenais GR, ; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–318
   PubMed Web of Science ®Google Scholar
• . Fernandes MB, Caldas HC, Martins LR, . Effects of polyunsaturated fatty acids (PUFAs) in the treatment of experimental chronic renal failure. Int Urol Nephrol. 2012;44(5):1571–1576
   PubMedGoogle Scholar
• . Brown SA, Brown CA, Crowell WA, . Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. J Lab Clin Med. 1998;131(5):447–455
   PubMedGoogle Scholar
• . Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1(4):780–786
   PubMed Web of Science ®Google Scholar
• . Lok CE, Moist L, Hemmelgarn BR, . Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA. 2012;307(17):1809–1816
   PubMedGoogle Scholar
• . Kshirsagar AV, Shoham DA, Bang H, Hogan SL, Simpson RJ Jr, Colindres RE. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis. 2005;46(5):812–819
   PubMedGoogle Scholar
• . Tamura Y, Murayama T, Minami M, Matsubara T, Yokode M, Arai H. Ezetimibe ameliorates early diabetic nephropathy in db/db mice. J Atheroscler Thromb. 2012;19(7):608–618
   PubMedGoogle Scholar
• . Mori Y, Hirano T. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol. Metabolism. 2012;61(3):379–388
   PubMedGoogle Scholar
• . Davis HR Jr, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis. 2011;215(2):266–278
   PubMedGoogle Scholar
• . Nakamura T, Sato E, Fujiwara N, . Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61(1):58–61
   PubMed Web of Science ®Google Scholar